IMVT
Immunovant, Inc.
There isn't enough reported data to score IMVT yet.
IMVT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IMVT's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
IMVT PE Valuation
IMVT has no meaningful PE right now: it lost money over the past year.
IMVT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IMVT's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
IMVT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.55 | +$0.28 |
| Q2 2026 | -$2.81 | +$0.03 |
| Q1 2026 | -$2.77 | -$0.04 |
| Q4 2025 | -$2.68 | -$0.08 |
| Q3 2025 | -$2.83 | -$0.63 |
| Q2 2025 | -$2.84 | -$0.93 |
| Q1 2025 | -$2.73 | -$0.85 |
| Q4 2024 | -$2.60 | -$0.76 |
IMVT lost $2.55 per share over the past year, about the same as its loss the year before.
IMVT Quarterly Revenue
IMVT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$83.2M | +$19.3M |
| Q2 2026 | -$124.4M | -$7M |
| Q1 2026 | -$95.1M | +$15.8M |
| Q4 2025 | -$92.3M | +$8.2M |
| Q3 2025 | -$102.5M | -$13.7M |
| Q2 2025 | -$117.4M | -$41M |
| Q1 2025 | -$110.8M | -$51M |
| Q4 2024 | -$100.6M | -$53.3M |
IMVT has burned cash in almost every quarter: −$395M over the past year, against −$431M the year before.
IMVT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +1.1M shares |
| 1 year | +19% | +33M shares |
| 3 years | +58% | +75.5M shares |
| 5 years | +89% | +97.6M shares |
| Available history | +404% | +166M shares |
IMVT has 207M diluted shares, up 19% from a year ago.
IMVT Net Leverage
IMVT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IMVT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.5 | Neutral |
| Stochastic | 27.7 | Neutral |
IMVT's weekly RSI is 54 (neutral) and its Stochastic is 28 (neutral).
IMVT PE vs Healthcare Sector
IMVT has no meaningful PE right now: it lost money over the past year.
IMVT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.9 | 13% above |
| 20 week MA | $36.3 | 3.3% below |
| 50 week MA | $31.2 | 12% above |
| 100 week MA | $24.8 | 41% above |
| 200 week MA | $26.1 | 34% above |
IMVT's trend is mixed: it's above four of its five weekly moving averages, and 34% above its 200-week average.
IMVT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.2 | $49.8 | +207% |
| 2021 | $49.8 | $7.96 | -84% |
| 2022 | $7.96 | $16.2 | +104% |
| 2023 | $16.2 | $42.1 | +160% |
| 2024 | $42.1 | $24.5 | -42% |
| 2025 | $24.5 | $26.2 | +6.8% |
| 2026 YTD | $26.2 | $35.1 | +34% |
IMVT's yearly returns have swung widely, from +207% in 2020 to −84% in 2021. It's up 34% so far in 2026.